Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s patents for its COVID-19 vaccine technology. The final written decisions remain sealed. U.S. Patent Nos. 10,933,127 (IPR2023-01359) and 10,702,600 (IPR2023-01358) are both titled “Betacoronavirus Mrna Vaccine.” Moderna competitors Pfizer and BioNTech filed two petitions for inter partes review (IPR) in August 2023 against certain claims of each of the patents, accusing Moderna of attempting “to coopt an entire field of mRNA technology.”
Recent Posts
- Congress and Courts Need to Look in the Mirror When Asking Why Medical Innovation is Declining
- USPTO Hiring Freeze Ends, Patent Examiners Wanted
- Judiciary Committee Votes Squires Through 20-2
- Disney and Universal Become Latest to Sue Midjourney Over Generative AI Service
- Stewart Says USPTO Wants Early Validity Challenges, Not Late IPRs